Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.

The San Diego, USA firm has simultaneously announced that the US Food and Drug Administration (FDA) has granted Orphan Drug ...

Braemar Hotels & Resorts (BHR) announced on Tuesday an upsizing of its board of directors with the appointment of Bob Ghassemieh as a new member.

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily ...

Pharmaceuticals announced that the primary and key secondary endpoints were met in the Phase 3 NIMBLE trial assessing ...

Opening Day of the 2025 N.J. cross country is quickly approaching, which means teams will be gearing up their lineups to ...

The company, founded in 2022, last year raised $52 million in a Series A funding round led by investors Eight Roads and 3E Bioventures.

This study presents useful findings on the molecular mechanisms driving female-to-male sex reversal in the ricefield eel (Monopterus albus) during aging, which would be of interest to biologists ...

Nucleic acid aptamers have attained significant prominence in diagnostics, therapeutics, and medical research owing to their ...

Cheers! The Rogue Broadband Brewfest is coming to the Jackson County Expo in September. Organizers say there will be over 70 ...